Similar global N-acetylaspartate in benign and non-benign multiple sclerosis patients of similar long disease duration

Daniel Rigotti¹, Lutz Acht.nihets², Oded Gonen¹, James Babbs¹, Yvonne Naegelin², Kerstin Bendfeld², Jochen Hirsch³, Michael Amann², Robert I Grossmans¹, Ludwig Kapos³, and Achim Gass⁴

¹Radiology, New York University School of Medicine, New York, NY, United States, ²Radiology, University Hospital Basel, Basel, Switzerland

Introduction:
Approximately 20% of relapsing-remitting multiple sclerosis (RR MS) patients exhibit a benign course defined as full functionality (Expanded Disability Status Scale [EDSS] ≤ 3.0) after at least 15 years of disease duration (1). Unfortunately, this diagnosis is only retrospective. Considering the high costs and side effects of MS treatment and its variable course, an early determination of individualized treatment is needed but lacking. Existing metrics, such as lesion load, have not adequately met this challenge; yet regional declines in the neuronal marker N-acetylaspartate (NAA) have correlated promisingly with clinical disability (2). Our goal, therefore, is to test whether clinically benign MS patients retain higher global concentrations of NAA (WBNAA) than their more profoundly disabled contemporaries.

Methods:
Lesion loads (both $T_1$ and $T_2$) and fractional brain parenchymal volume, a marker of atrophy (fBPV) were obtained from MR imaging and WBNAA from proton MR spectroscopy (3) in (i) 24 benign MS patients: 23.1±7.2 years disease duration, median EDSS score of 2.0, (ii) 16 non-benign patients: 21.0±4.0 years disease duration, median EDSS of 4.0 and (iii) 17 healthy, age-matched controls.

Results:
Sample MP-RAGE images and spectra from each subject group (control: a, benign: b, non-benign: c) are shown in Fig.1. They illustrate the relative similarity between the two phenotypes in terms of atrophy (which is much higher than in controls), and $T_1$ hypointense lesion. Indeed, the controls’ fBPV, 86.2±3.3%, was significantly higher than either patient group (benign: 76.4±6.7%, non-benign: 76.8±9.1%, $p<0.01$), as shown in Fig.2. Also displayed in Fig.2 is that the non-benign group had higher $T_2$ hypointense lesion load (4.5±5.8 vs. 2.1±2.2 cm$^3$ ($p=0.031$)), but indistinguishable $T_2$ hyperintense lesion volumes from the benign group (9.8±7.4 vs. 6.2±5.5 cm$^3$, $p<0.05$). The controls’ 12.2±2.3 mM WBNAA was higher than the benigns’ 10.5±2.4 mM, and non-benigns’ 10.1±2.3 mM, ($p<0.04$ for both), yet, as shown in Fig.3, there was no difference between patient groups ($p=0.7$).

Discussion:
Neuronal integrity, reflected by WBNAA concentration similar to healthy contemporaries, does not appear to be characteristic of benign MS. Despite their low level of clinical disability. In fact, the similar WBNAA rate of loss of benign and non-benign MS patients of similar disease duration, may indicate that “a benign course” likely reflects a combination of fortuitous sparing of the strategic brain regions that influence the EDSS score and better compensatory mechanisms, rather than less atrophy and/or neurodegeneration. This finding, if further substantiated in additional (serial) studies has implications for therapeutic decisions.